Amplia takes aim at billion-dollar pancreatic cancer drug market
Amplia Therapeutics has initiated a pivotal trial for narmafotinib, targeting pancreatic cancer. The trial aims to enhance treatment efficacy through daily dosing in combination with standard chemotherapy. This approach seeks to break down the protective barriers of tumors, potentially improving outcomes for patients.
- ▪Amplia Therapeutics is developing narmafotinib to treat pancreatic cancer.
- ▪The Phase 2b study will test daily dosing of narmafotinib alongside conventional chemotherapy.
- ▪Patient enrollment for the trial is expected to begin in Q4 2026 across multiple clinical sites in Australia.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-05-19T08:36:09Z","datePublished":"2026-05-19T08:36:09Z","description":"Amplia Therapeutics has launched a pivotal registration-enabling trial of narmafotinib for pancreatic cancer, testing better efficacy with daily dosing.","headline":"Amplia takes aim at billion-dollar pancreatic cancer drug market","keywords":"Bulls N' Bears, Shares, Sharemarket","author":[{"@type":"Person","name":"Murray…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Sydney Morning Herald.